BIOGEN INC

NASDAQ: BIIB (Biogen Inc.)

Kemas kini terakhir: 21 Mar, 11:25PM

140.90

-0.48 (-0.34%)

  • 1H -0.34%
  • 5H 14.57%
  • 1B -1.84%
  • 6B -25.67%
  • Tahun Ke Tarikh -6.07%
  • 1T -26.68%
  • 5T -58.87%
Penutupan Terdahulu 141.38
Buka 141.24
Jumlah Dagangan 3,437,606
Purata Dagangan (3B) 1,521,561
Modal Pasaran 20,694,546,432
Harga / Pendapatan (P/E TTM) 12.64
Harga / Pendapatan (P/E Ke hadapan) 7.33
Harga / Jualan (P/S) 1.74
Harga / Buku (P/B) 1.01
Julat 52 Minggu
128.51 (-8%) — 238.00 (68%)
Tarikh Pendapatan 22 Apr 2025 - 28 Apr 2025
Margin Keuntungan 16.87%
Margin Operasi (TTM) 21.51%
EPS Cair (TTM) 11.18
Pertumbuhan Hasil Suku Tahunan (YOY) 2.90%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 6.80%
Jumlah Hutang/Ekuiti (D/E MRQ) 40.18%
Nisbah Semasa (MRQ) 1.35
Aliran Tunai Operasi (OCF TTM) 2.88 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 3.27 B
Pulangan Atas Aset (ROA TTM) 5.29%
Pulangan Atas Ekuiti (ROE TTM) 10.36%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Bercampur Menaik
Drug Manufacturers - General (Global) Bercampur Menaik
Stok Biogen Inc. Menurun Menurun

AISkor Stockmoo

-0.1
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -2.5
Purata -0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BIIB 21 B - 12.64 1.01
AZN 230 B 2.26% 30.43 6.19
SNY 127 B 8.05% 20.32 1.48
AMGN 152 B 3.23% 37.39 26.14
GILD 132 B 2.93% 278.11 6.68
GRFS 6 B - 28.00 0.710

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Mid Value
% Dimiliki oleh Orang Dalam 0.21%
% Dimiliki oleh Institusi 94.34%
479.80479.80390.40390.40301.00301.00211.60211.60122.20122.20Harga Sasaran MedianQ2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
128.51 (-8%) — 238.00 (68%)
Julat Harga Sasaran
135.00 (-4%) — 265.00 (88%)
Tinggi 265.00 (Canaccord Genuity, 88.08%) Beli
Median 210.00 (49.04%)
Rendah 135.00 (Piper Sandler, -4.19%) Pegang
Purata 192.82 (36.85%)
Jumlah 6 Beli, 5 Pegang
Harga Purata @ Panggilan 136.65
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Morgan Stanley 09 Apr 2025 152.00 (7.88%) Pegang 120.49
13 Feb 2025 157.00 (11.43%) Pegang 138.45
Piper Sandler 18 Feb 2025 135.00 (-4.19%) Pegang 136.57
BMO Capital 13 Feb 2025 139.00 (-1.35%) Pegang 138.45
Canaccord Genuity 13 Feb 2025 265.00 (88.08%) Beli 138.45
Citigroup 13 Feb 2025 145.00 (2.91%) Pegang 138.45
28 Jan 2025 160.00 (13.56%) Pegang 145.49
Goldman Sachs 13 Feb 2025 245.00 (73.88%) Beli 138.45
HC Wainwright & Co. 13 Feb 2025 241.00 (71.04%) Beli 138.45
RBC Capital 13 Feb 2025 225.00 (59.69%) Beli 138.45
Scotiabank 13 Feb 2025 224.00 (58.98%) Beli 138.45
Truist Securities 13 Feb 2025 210.00 (49.04%) Beli 138.45
Wells Fargo 13 Feb 2025 140.00 (-0.64%) Pegang 138.45
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
15 Apr 2025 Pengumuman Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
15 Apr 2025 Pengumuman Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
02 Apr 2025 Pengumuman Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
02 Apr 2025 Pengumuman Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
24 Mar 2025 Pengumuman Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
24 Mar 2025 Pengumuman Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
11 Mar 2025 Pengumuman Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
11 Mar 2025 Pengumuman Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
28 Feb 2025 Pengumuman The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
18 Feb 2025 Pengumuman Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
18 Feb 2025 Pengumuman Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
18 Feb 2025 Pengumuman Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
12 Feb 2025 CNBC Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short 
31 Jan 2025 Pengumuman Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
31 Jan 2025 Pengumuman Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
27 Jan 2025 Pengumuman Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
26 Jan 2025 Pengumuman FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
26 Jan 2025 Pengumuman FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
26 Jan 2025 Pengumuman FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
23 Jan 2025 Pengumuman FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
23 Jan 2025 Pengumuman FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Papar semua
141.73141.73130.21130.21118.68118.68107.16107.1695.6395.63Apr 2Apr 2Apr 3Apr 3Apr 4Apr 4Apr 7Apr 7Apr 8Apr 8Apr 9Apr 9Apr 10Apr 10Apr 11Apr 11

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0000.000-2.000-2.000-4.000-4.000-6.000-6.000-8.000-8.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda